Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Xeris Biopharma (Nasdaq: XERS) will report first quarter 2026 financial results before U.S. market open on May 7, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Conference Call to be Held at 8:30 a.m. ET
Interested parties may pre-register for the call here or via the “Events” section of the Investor Relations website. It is recommended that attendees register 15 minutes prior to the scheduled webcast.
The webcast, replay and other information related to the event can be accessed on the investor website https://xerispharma.com/investor-relations.
About Xeris
Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20260423117811/en/
Xeris Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.